share_log
Breakings ·  Dec 20 19:02

The Stoxx Europe 600 Index fell by 2%, reaching 496.52 points. Novo-Nordisk A/S's stock price plummeted by 27%, marking the largest single-day drop in 22 years. This was due to the disappointing trial results of Novo-Nordisk A/S's weight loss drug CagriSema. On Friday, Novo-Nordisk A/S announced that its experimental next-generation obesity drug Cagrisema helped overweight patients lose 22.7% of their weight in a late-stage trial, falling short of the expected 25%, leading to a significant decline in its stock price.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment